FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream ...
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma Using primary samples from the InterMEL study, a retrospective cohort of cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback